HER2 exon 20 insertion
HER2 exon 20 insertion
Overview
HER2 exon 20 insertion refers to an activating alteration in the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase involved in cell growth and signaling. Exon 20 insertions are a class of in-frame insertion mutations that can alter receptor conformation and promote oncogenic signaling. In clinical oncology, HER2 exon 20 insertion is most prominently discussed in non-small cell lung carcinoma (NSCLC), where it is recognized as a therapeutically relevant molecular subtype and a target for HER2-directed treatment strategies.
Biologically, HER2 is a major therapeutic target in cancer because it can drive downstream signaling pathways such as ERK-mediated proliferation and survival. Although HER2 exon 20 insertion is distinct from HER2 amplification or overexpression, it is still clinically important because it can confer sensitivity to selected HER2-targeted agents, including antibody-drug conjugates. At the same time, HER2-directed therapy can be associated with toxicity, and the mutation has been studied in the context of treatment response and adverse events.
Focus of Latest Publications
Recent publications involving HER2 exon 20 insertion have focused primarily on HER2-targeted therapy in non-small cell lung carcinoma, with trastuzumab deruxtecan (T-DXd) as the central agent. In a reported case, a 78-year-old woman with NSCLC harboring a HER2 exon 20 insertion developed grade 1 T-DXd-induced interstitial lung disease during third-line treatment. Oral corticosteroids led to radiologic improvement, and T-DXd was successfully re-administered at a reduced dose. The patient then received eight additional cycles, with tumor regression and no recurrence of ILD, highlighting the importance of early detection and management of pulmonary toxicity to preserve treatment benefit.
Across the broader set of recent HER2-focused studies, investigators also examined HER2 as a therapeutic target in other cancer contexts and in platform technologies relevant to HER2-directed care. These included a real-world analysis of HER2-positive gastroesophageal cancer treated with trastuzumab plus chemotherapy, studies of HER2-targeting antibody-drug conjugates in metastatic breast cancer, and engineering approaches using HER2-binding aptamers, nanobodies, and optogenetic antibody systems. Although these reports did not specifically study HER2 exon 20 insertion, they reinforce the expanding toolkit of HER2-directed diagnostics and therapeutics that provides the clinical backdrop for mutation-specific treatment strategies.
Additional recent work addressed HER2 biology and HER2-targeted intervention more generally, including a study showing that HER2 deficiency can cause a developmental disorder with growth retardation and craniofacial malformations, and another demonstrating that chondroitinase ABC can enhance trastuzumab activity by improving HER2 engagement in glycan-rich pancreatic cancer cells. Together with the NSCLC case report, these publications underscore the continuing clinical and translational interest in HER2 as a target, while the HER2 exon 20 insertion literature in this set remains centered on T-DXd efficacy and toxicity management.